Y2 selective receptor agonists for therapeutic interventions

Details Y2 selective receptor agonists for therapeutic interventions Y2 selective receptor agonists for therapeutic interventions

2005-09-21

2010-12-14

Lukton, David (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C514S012200

Reexamination Certificate

active

07851590

ABSTRACT:
The modified human PP peptides (i) [Lys4,Leu17,Ser30,Gln34]hPP, (ii) Lys4,Leu17,Thr30,Gln34]hPP; and (iii) [Lys4,Leu17,oxidised Met30,Gln34]hPP wherein “oxidised Met” may be the sulfoxide or sulfone, and certain analogues and derivatised forms thereof as referred to in the specification, are selective agonists of the Y2 receptor relative to the Y1 and Y4 receptors, and are useful for, for example, appetite control and therapeutic angiogenesis.

REFERENCES:
patent: 5604203 (1997-02-01), Balasubramaniam
patent: 5830434 (1998-11-01), Taylor
patent: 6458381 (2002-10-01), Sourovoi
patent: 6588708 (2003-07-01), Wang
patent: 7459432 (2008-12-01), Cowley et al.
patent: 2004/0214772 (2004-10-01), Quay
patent: 2008/0255046 (2008-10-01), Schwartz et al.
patent: 2008/0261871 (2008-10-01), Schwartz
patent: 2008/0269114 (2008-10-01), Schwartz
patent: 2009/0118178 (2009-05-01), Schwartz
patent: 2009/0186811 (2009-07-01), Schwartz
patent: WO 92/07935 (1992-05-01), None
patent: WO 95/17906 (1995-07-01), None
patent: WO 98/11126 (1998-03-01), None
patent: WO 99/46283 (1999-09-01), None
patent: WO 02/47712 (2002-06-01), None
patent: WO 03/026591 (2003-04-01), None
patent: WO 2005/053726 (2005-06-01), None
patent: WO 2005/077094 (2005-08-01), None
patent: WO 2005/089786 (2005-09-01), None
patent: WO 2005/089789 (2005-09-01), None
patent: WO 2005/089790 (2005-09-01), None
patent: WO 2007/038942 (2007-04-01), None
patent: WO 2007/038943 (2007-04-01), None
patent: WO 2008/132435 (2008-11-01), None
patent: 2009/007714 (2009-01-01), None
Cabrele, C., Peptides (New York, NY, United States) 22(3), 365-378, 2001.
McCrea, K., Regulatory Peptides 87(1-3), 47-58, 2000.
Asakawa et al., “Characterization of the Effects of Pancreatic Polypeptide in the Regulation of Energy Balance,” Gastroenterology 124, 1325-36, 2003.
Balasubramanian et al., “Syntheses and Receptor Affinities of Partial Sequences of Peptide YY (PYY),”Peptide Res. 1, 1988, Sep. 1988.
Bard et al., “Cloning and Functional Expression of a Human Y4 Subtype Receptor for Pancreatic Polypeptide, Neuropeptide Y, and Peptide YY,” J. Biol. Chem. 270, 26762-65, Nov. 10, 1995.
Batterham et al., “Gut Hormone PYY3-36 Physiologically Inhibits Food Intake,”Nature418, 650-54, Aug. 8, 2003.
Batterham et al., “Pancreatic Polypeptide Reduces Appetite and Food Intake in Humans,”J. Clin. Endocrinol. Metab. 88, 3989-92, Aug. 2003.
Berntson et al., “Pancreatic Polypeptide Infusions Reduce Food Intake in Prader-Willi Syndrome,”Peptides 14, 4970503, 1993.
Dumont et al., “Characterization of a new neuropeptide Y Y5 agonist radioligand: [<125>I][cPP(1-7), NYP(19-23), Ala<31>, Aib<32>, Gln<34>]hPP,” Neuropeptides, vol. 38, No. 4, pp. 163-174, Aug. 2004.
Eberlein et al., “A New Molecular Form of PYY: Structural Characterization of Human PYY (3-36) and PYY (1-36),”Peptides 10, 797-803, 1989.
Félétou Michel et al., “Neuropeptide Y2 receptors as drug targets for the central regulation of body weight,” Current Opinion in Investigational Drugs, vol. 6, No. 10, pp. 1002-1011, Oct. 2005.
Fuhlendorff J et al: “The anti parallel pancreatic polypeptide fold in the binding of neuropeptide Y to Y-1 and Y-2 receptors” Jul. 15, 1990, Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, US, pp. 11706-11712, XPQ02339077 ISSN: 0021-9258.
Gehlert et al., “Characterization of the Peptide Binding Requirements for the Cloned Human Pancreatic Polypeptide-Preferring Receptor,”Mol. Pharmacol. 50i, 112-18, 1996.
Gerald et al., “Expression Cloning and Pharmacological Characterization of a Human Hippocampal Neuropeptide Y/Peptide YY Y2 Receptor Subtype,” J. Biol. Chem. 270, 26758-61, 1995.
Grundemar, “Characterization of the Receptor Response for the Neuropeptide Y-Evoked Suppression of Parasympathetically-Mediated Contractions in the Guinea Pig Trachea,”Regulatory Peptides 71, 97-101, 1997.
Jorgensen et al., “Structure-function studies on neuropeptide Y and pancreatic polypeptide: Evidence for two PP-fold receptors in vas deferens,” Eur. J. Pharmacol. 186, 105-14, 1990.
Katsuura et al., “Roles of Pancreatic Polypeptide in Regulation of Food Intake,”Peptides 23, 323-29, 2002.
Keire et al., “Structure and receptor binding of PYY analogs,” Peptides, vol. 23, No. 2, pp. 305-321, Feb. 2002.
Kirby et al., “Defining Structural Requirements for Neuropeptide Y Receptors Using Truncated and Conformationally Restricted Analogues,”J. Med. Chem. 36, 385-93, 1993.
Kurtzhals et al., “Albumin Binding of Insulins Acylated with Fatty Acids: Characterization of the Ligand-Protein Interaction and Correlation between Binding Affinity and Timing of the Insulin Effect in Vivo,” Biochemical Journal, vol. 312, No. 3, pp. 725-731, 1995.
Larsen et al., “The Neuropeptide Y—Y4/ Receptor is Highly Expressed in Neurones of the Rat Dorsal Vagal Complex,”Mol. Brain Res. 48, 1-6, 1997.
Lerch et al., “Bovine Pancreatic Polypeptide (bPP) Undergoes Significant Changes in Conformation and Dynamics upon Binding to DPC Micelles,”J. Mol. Biol. 322, 1117-33, 2002.
Lerch et al., “Structural Similarities of Micelle-bound Peptide YY (PYY) and Neuropeptide Y (NPY) are Related to their Affinity Profiles at the Y Receptors,”J. Mol. Biol. 339, 1153-68, Jun. 18, 2004.
Medeiros & Turner, “Post-Secretory Processing of Regulatory Peptides: The Pancreatic Polypeptide Family as a Model Example,”Biochemie 76, 283-87, 1994.
Murase Sachiko et al., “Acylation of the α Group in Neuropeptide Y(12-36) Increases Binding Affinity for the Y2Receptor,”Abstr. J. Biochem(Tokyo) 119, 37-41, 1996.
Nygaard et al., “The PP-Fold Solution Structure of Human Polypeptide YY and Human PYY3-36 as Determined by NMR,”Biochem. 45, 8350-57, 2006.
Parker et al., “GR231118 (1229U91) and other analogs of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists,” Eur. J. Pharmacol. 349, 97-105, 1998.
Rossi et al., “Central nerous system neuropeptides involved in obesity,” Handbook of Exp. Pharmacol. 149, 313-41, 2000.
Sheffield, “Modification of clearance of therapeutic and potentially therapeutic proteins,” Cardiovascular and Haematological Disorders, vol. 1, No. 1, pp. 1-22, Jun. 2001.
Walker et al., “A Structure-Activity Analysis of the Cloned Rat and Human Y4 Receptors for Pancreatic Polypeptide1,2,”Peptides 18, 609-12, 1997.
Walker et al., “Peptide Receptor Structure and Function I,”Soc. Neuroscience Abs. 21, 1012, Nov. 11, 1995.
Walker et al., “Binding of NPY8 PYY and PP Analogs to cloned human Y2 and Y4 receptors” Society for Neuroscience Abstracts, Society for Neuroscience, US, vol. 21, No. 1/3 Nov. 11, 1995.
UnitProt Accession No. P01298, Apr. 3, 2007.
U.S. Appl. No. 12/597,090, filed Oct. 22, 2009 (unpublished).
Yao Shenggen et al., “Stabilization of the Helical Structure of Y2-Selective Analogues of Neuropeptide Y by Lactam Bridges,”J. Med. Chem. 45, 2310-18, May 23, 2002.

Affiliated with

Also associated with

Rating

Y2 selective receptor agonists for therapeutic interventions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Y2 selective receptor agonists for therapeutic interventions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Y2 selective receptor agonists for therapeutic interventions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4196770